Picture a startup founder walking away from an acquisition with a substantial payout and paying exactly $0 in federal capital gains tax thanks to QSBS. That outcome is not a financial loophole. It is a deliberate federal incentive designed specifically to reward the intense risks associated with building and investing in early-stage companies.
For founders, early employees, and angel investors, the QSBS exclusion under Section 1202 of the tax code is perhaps the single most powerful tax benefit available in the United States today.
With the recent passage of the OBBBA, signed into law on July 4, 2025, the landscape for this tax benefit has dramatically shifted in favor of entrepreneurs. The new legislation raised the lifetime exclusion cap to $15 million and introduced a highly anticipated tiered exclusion schedule that provides partial benefits for earlier exits.
This guide explains how life sciences and technology startups can secure this tax break, avoid costly structural mistakes, and protect their equity value upon exit.
What Is QSBS Under Section 1202?
QSBS is Qualified Small Business Stock, a specialized corporate tax classification that allows startup founders and early investors to exclude up to 100% of their federal capital gains tax upon the sale of eligible shares. When you sell stock that meets all the strict federal criteria, you effectively bypass the standard capital gains tax rates that would normally consume a significant portion of your hard-earned exit proceeds.
Crucially, this benefit mandates a very specific entity structure. The equity must be domestic C-Corporation stock. If you run a Limited Liability Company (LLC) or an S-Corporation, your underlying equity does not qualify for the exclusion.
Many founders initially form an LLC to capture early pass-through losses, unaware that they are permanently locking themselves out of the ultimate exit incentive. This structural requirement is why proper entity selection and early legal review form the foundation of any successful long-term tax plan under Section 1202.
The OBBBA Changes: What’s New in 2025-2026
The OBBBA modernized the federal tax framework to better reflect current venture capital realities and exit timelines. The most profound update is the elimination of the rigid five-year holding requirement for any exclusion. The legislation introduced a tiered exclusion schedule. Now, founders earn a 50% exclusion after holding their shares for three years, a 75% exclusion after four years, and the full 100% exclusion after five years.
Simultaneously, the federal exclusion cap increased significantly. Founders can now exclude up to $15 million or 10 times their adjusted basis, whichever number is greater. This is a significant jump from the previous $10 million limit. To accommodate the higher early-stage valuations common in modern technology sectors, the gross assets test also increased from $50 million to $75 million.
It is critical to understand that these changes only apply to stock issued AFTER July 4, 2025. Older shares remain strictly bound by the legacy rules, meaning they are still subject to the old $10 million cap, the $50 million gross assets limit, and the rigid five-year wait for any exclusion. In practice, this creates a complex “mixed cap table” problem.
Different shareholders within the exact same startup will face substantially different tax liabilities during the exact same exit, depending entirely on the specific date their individual shares were officially issued.
Who Qualifies: The 5 Core Requirements
Securing the gain exclusion requires strict, unwavering adherence to IRS rules from the moment of incorporation until the day the company is sold. As outlined in IRS Publication 550, the five core requirements include:
- C-Corporation Requirement: The company must be a domestic C-Corporation at the exact time the stock is issued and during substantially all of your holding period.
- Gross Assets Test: The corporation’s aggregate gross assets must not have exceeded $75 million at any time before or immediately after the stock issuance. This includes cash and the adjusted basis of other property held by the corporation.
- Qualified Trade or Business: At least 80% of the corporation’s assets (by value) must be actively used in the conduct of a qualified trade or business. Holding too much idle cash can jeopardize this test.
- Holding Period: You must hold the QSBS for at least three to five years to access the new tiered exclusion benefits.
- Original Issuance: You must acquire the stock directly from the company in exchange for money, property, or services. Purchasing shares on the secondary market from another shareholder automatically disqualifies the stock.
Life Sciences and Biotech: Why QSBS Matters Most
The Internal Revenue Code explicitly excludes “health services” from eligibility. This specific wording frequently causes significant confusion for biotech and life sciences founders. The crucial legal distinction centers on whether your company operates as a service provider or a product developer.
Biotech and pharmaceutical companies that actively develop proprietary products, such as novel drugs, medical devices, or complex diagnostics, generally qualify because they are classified as product companies, not health services.
This is a vital nuance. We have seen founders we work with almost abandon their entire tax strategy because a generalist accountant wrongly flagged the word “health” in their business plan and assumed they were disqualified.
For life sciences startups, the financial benefits are substantial. Successful clinical trials and FDA approvals inevitably lead to significant valuation increases upon exit, generating substantial capital gains.
Furthermore, because life sciences product development cycles typically span five to ten years, biotech founders naturally satisfy the long five-year holding period required for a full 100% tax exclusion. Their operational timeline perfectly aligns with the ultimate tax benefit.
The Holding Period Trap
The new tiered system offers new flexibility, but early exits still carry significant tax consequences that catch many founders off guard. Selling at the three-year mark secures a 50% exclusion, but the remaining unexcluded gain is heavily taxed at a 28% capital gains rate plus a 3.8% Net Investment Income Tax (NIIT). Waiting just two more years eliminates that specific tax burden.
A hidden risk lies within your vesting schedule. Filing an 83(b) election within 30 days of your grant can start your holding period at issuance rather than at vesting – a critical timing decision that should be reviewed with counsel. We have seen a tech founder exit in year four, expecting full protection, only to discover that timing issues with their equity grants left part of their gain exposed to unexpected taxes.
If an acquisition forces a sale before the requisite holding period is met, founders can utilize a Section 1045 rollover. This mechanism allows you to roll the gain into a new qualified small business within 60 days, so the prior holding period carries over to the replacement stock.
Which Businesses Don’t Qualify for Section 1202
Congress designed this federal incentive specifically to spur high-risk innovation, engineering, and job creation in product and technology sectors. Consequently, many traditional, low-risk, or heavily localized businesses are strictly excluded from the benefit. Disqualified fields include:
- Health services, law, accounting, consulting, and financial services
- Performing arts and athletics
- Banking, insurance, financing, leasing, and investing
The “services exclusion” remains the most frequently misunderstood element of the law. If your startup’s primary value relies heavily on the individual knowledge, reputation, or personal skill of its employees, rather than a scalable proprietary technology, software platform, or physical product, you likely fall into the excluded services category.
Again, distinguishing a biotech product company from a medical service provider is essential.
State Conformity: New Jersey, Pennsylvania, and Beyond
While the federal government provides significant relief, state-level conformity varies significantly and requires careful geographic planning. For founders based in states with no income tax, like Texas, Florida, Nevada, or Wyoming, the gain exclusion is purely a federal matter. In the Northeast, the landscape is actively shifting.
New Jersey recently made a legislative change by adopting the federal framework. For tax years beginning on or after January 1, 2026, New Jersey fully aligns with the federal rules, explicitly including the new OBBBA enhancements and the $15 million cap. This creates meaningful wealth preservation opportunities for local startups. We work with founders across NJ and NY to structure their entities specifically to capture these newly aligned state benefits.
Conversely, Pennsylvania does not comply with federal rules. Founders residing in PA will still pay state income tax on their entire capital gain, regardless of their federal exemptions. California also actively denies the exclusion, routinely subjecting founders to state taxes of up to 13.3% on their liquidity events.
QSBS Stacking: Multiplying the $15M Cap
What happens when your projected exit far exceeds the new $15 million limit? Sophisticated founders can utilize an advanced legal strategy known as stacking to multiply their available limit. Because the $15 million cap applies strictly on a per-taxpayer basis, you can legally transfer eligible shares to separate taxpayers, such as family members or specific types of trusts.
For example, a founder could gift eligible shares to three separate, carefully drafted non-grantor trusts for their children. Each independent trust claims its own unique $15 million cap. Combined with the founder’s personal cap, a single family of four could legally shelter up to $60 million from federal capital gains tax.
Timing and execution are vital for this strategy. Gifts must be completed well before any binding sale agreement or letter of intent is signed. If you wait until a deal is essentially finalized, the IRS will invoke the assignment-of-income doctrine, collapsing the trusts and nullifying the separate limits. This requires meticulous drafting by specialized legal counsel.
Common QSBS Mistakes Founders Make
Even minor administrative errors early in a startup’s life cycle can permanently destroy your eligibility. The federal tax code offers no forgiveness for procedural missteps. The most frequent mistakes include:
- Forming as an LLC: Operating as a partnership or LLC provides early flexibility but invalidates the stock for federal exemption purposes. The equity must be from a C-Corp.
- Selling Too Early: Cashing out before the absolute minimum three-year mark forfeits the tiered exclusion entirely, triggering standard capital gains rates on the entire sum.
- Missing the Gross Assets Window: Raising large early-stage funding rounds that push the company’s gross assets above the $75 million threshold right before you issue your own common shares.
- Poor Documentation: Failing to maintain contemporaneous corporate records proving the company continuously met the active business requirements. You cannot prove the exclusion’s eligibility on an IRS audit without an impeccable paper trail.
- Late-Stage Gifting: Attempting to stack separate limits after acquisition negotiations have already started, which triggers the assignment-of-income trap.
A founder’s initial tax basis is almost always $0 upon incorporation. Because the law allows for the greater of $15 million or 10 times the basis, most founders will rely strictly on the flat $15 million cap.
2026 Planning Outlook for Section 1202
The adoption of the federal framework by New Jersey starting January 1, 2026, fundamentally reshapes the Northeast startup ecosystem. For companies operating in the region, the combined state and federal tax savings demand immediate structural attention.
Additionally, statutory inflation adjustments to the new $75 million threshold are slated to begin in 2027, which will offer slightly more operational runway for highly capital-intensive tech startups.
Early planning is mandatory. If you are currently operating a profitable startup as an LLC, the exact timing of your conversion to a C-Corp dictates exactly when your holding period clock begins. Every month you delay the necessary conversion is a month added to your eventual exit timeline.
Why Legal Review Matters
Securing this specific tax break is a highly technical, rigidly enforced process fraught with expensive pitfalls. Relying on generic advice or templates can be disastrous. Crowley Law LLC provides precise entity structuring, meticulous feasibility analysis, and thorough documentation to safeguard your eventual exit. Our deep technical knowledge in both technology and biotechnology ensures your corporate framework actively supports your long-term liquidity event.
How Crowley Law Helps with QSBS Planning
Crowley Law LLC structures QSBS-eligible equity and entity frameworks for life sciences and technology startups. We help founders choose the right corporate structure, time their C-Corp conversion, and document Section 1202 eligibility before a liquidity event turns a tax-free exit into a multimillion-dollar tax bill.
Planning your QSBS strategy early helps preserve the full exclusion, avoid disqualifying mistakes, and protect your wealth before an acquisition or IPO. Contact Crowley Law to speak with a startup tax planning attorney, whether you need initial entity structuring or a complete QSBS eligibility review.
Contact Us | Schedule a Consultation
Frequently Asked Questions (FAQs)
| Question | Answer |
| Does my biotech startup qualify for QSBS if Section 1202 excludes ‘health’ businesses? | Yes, typically. The statutory exclusion specifically targets “health services” (like local clinics, doctors’ offices, or nursing entities). Biotech startups developing proprietary products, such as novel medical devices, diagnostics, or therapeutics, generally qualify as product companies rather than disqualified service providers. |
| What happens to my QSBS if I sell before five years? | Under the new OBBBA rules, selling between three and four years grants a 50% exclusion, while selling between four and five years grants a 75% exclusion. Exiting before the strict three-year mark nullifies the benefit, subjecting the entire gain to standard taxes. |
| Can I get QSBS benefits if my company started as an LLC? | Only shares issued while the company is officially operating as a C-Corporation are eligible. If you start as an LLC, you must officially convert to a C-Corp. Crucially, your QSBS holding period generally begins at the date of the C-Corp conversion, though the specifics depend on how the conversion is structured. |
| Does New Jersey follow the federal Section 1202 exclusion? | Yes, beginning with tax years on or after January 1, 2026, New Jersey officially conforms to the federal rules. This allows local startup founders to exclude substantial capital gains at the state level in addition to their federal savings. |
| How does QSBS stacking actually work? | Stacking involves carefully gifting eligible shares to separate taxpayers, such as meticulously drafted non-grantor trusts or family members, well before a sale agreement is imminent. Each distinct taxpayer entity can then legally claim its own separate $15 million limit upon exit. |
| What is the difference between the $15 million cap and the 10x basis rule? | Section 1202 allows you to exclude the greater of a flat $15 million or 10 times your adjusted basis in the stock. Since a founder’s basis is usually exactly $0 upon early incorporation, founders typically rely on the $15 million flat cap, while later-stage investors might benefit more from the 10x rule. |
| When should I start planning for QSBS? | Planning should ideally begin before formal incorporation. Choosing the wrong entity type, failing to file an 83(b) election, or issuing shares improperly can permanently disqualify your hard-earned equity, making early legal review essential. |